Progenity Launches Strategic Transformation into Biotech Company, Eliminating Costs of Progenity Genetics Lab and Focusing on Robust, Innovative R&D Pipeline
02 juin 2021 07h00 HE
|
Progenity, Inc.
Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations – from more than $180 million currently to...
Progenity Provides Results from Key Study for Its Targeted Therapeutics Program
26 mai 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced results from a further study for the company’s Targeted Therapeutics...
Sean Lavin, MD, Joins Progenity as Vice President, Business Development, Strategy, and Investor Relations
25 mai 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Sean Lavin, M.D. as Vice President, Business...
Progenity Announces Poster Presentations at Digestive Disease Week 2021
24 mai 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the presentation of two posters related to the company’s Targeted...
Progenity Joins Global Call to Raise Awareness of Preeclampsia in Pregnancy on World Preeclampsia Day – May 22nd
21 mai 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, May 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
Progenity Provides Corporate Update and Reports First Quarter 2021 Financial Results
13 mai 2021 16h03 HE
|
Progenity, Inc.
Reports revenues of $24.5 million in the first quarter of 2021, up 72% from prior quarter Announced pre-validation data for its Preecludia™ test showed strong performance consistent with...
Progenity Provides Preliminary Results from Key Studies for its Targeted Therapeutics Program
12 mai 2021 07h29 HE
|
Progenity, Inc.
SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced preliminary results, subject to final audited study reports by its...
Progenity Receives Funding from Crohn’s & Colitis Foundation IBD Ventures Fund to Develop Drug Delivery System for IBD
11 mai 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
Progenity to Report First Quarter 2021 Financial Results and Provide Corporate Update
06 mai 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Provides Key Update Regarding its Preecludia™ Test for Preeclampsia
05 mai 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...